Clinical Report: Placing Argentina on the Clinical Trials Map
Overview
Argentina is emerging as a significant player in global ophthalmology clinical trials, with improved research infrastructure and successful participation in major studies. The establishment of high-quality clinical trial sites has enhanced the country's reputation among international sponsors.
Background
The advancement of clinical trials is crucial for the development of new therapies and improving patient outcomes. Historically, clinical trials have been concentrated in Western Europe and North America, but there is a growing trend to include Latin America, particularly Argentina, due to its diverse population and evolving regulatory environment. Strengthening research capabilities in Argentina can facilitate access to innovative treatments for local patients.
Data Highlights
No specific numerical data provided in the source material.
Key Findings
- Argentina has established itself as a reliable partner for global ophthalmology studies.
- Over 10 clinical trials were conducted at the Charles Research Center in Buenos Aires in 2025, enrolling over 160 patients.
- Argentina's regulatory body, ANMAT, has aligned its Good Clinical Practice standards with international guidelines, enhancing the country's research credibility.
- Successful participation in multicenter trials like RIDE, RISE, and VIEW 2 has demonstrated Argentina's capability to meet international research standards.
- Demographic diversity in Argentina provides a unique opportunity for clinical trials to address a wide range of patient needs.
Clinical Implications
Healthcare professionals in Argentina can leverage the improved clinical trial infrastructure to enhance patient care and access to new therapies. The alignment of local regulations with international standards ensures that trials conducted in Argentina meet global expectations for quality and ethics.
Conclusion
The ongoing development of clinical trial capabilities in Argentina represents a significant opportunity for advancing ophthalmic research and improving patient outcomes. Continued investment in research infrastructure will further solidify Argentina's role in the global clinical trials landscape.
References
- The ASCO Post, 2018 -- Changing Negative Perceptions on the Impact of Clinical Trials in Brazil
- The ASCO Post, 2011 -- ASCO’s International Clinical Trials Workshop Educates Nascent Researchers on the Inner Workings of Clinical Trials
- Drugs - Real World Outcomes, 2025 -- Evaluation of Brigatinib's Safety and Efficacy in Patients with ALK-Positive Metastatic Non-Small Cell Lung Cancer in Argentina: Insights from a Post-Marketing Surveillance Analysis
- The ASCO Post, 2015 -- Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Argentina
- Overview of ICH, 2024 -- Overview of ICH
- Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University
- Overview of ICH
- Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
